Terms: = Kidney tumors AND EPAS1, MOP2, 2034, ENSG00000116016, PASD2, HIF2A, Q99814 AND Treatment
20 results:
1. Boosting Clear Cell Renal Carcinoma-Specific Drug Discovery Using a Deep Learning Algorithm and Single-Cell Analysis.
Wang Y; Chen X; Tang N; Guo M; Ai D
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612943
[TBL] [Abstract] [Full Text] [Related]
2. Genitourinary cancers updates: highlights from ASCO 2023.
Qin Q; Sheffield H; Taasan SM; Wang AZ; Zhang T
J Hematol Oncol; 2023 Nov; 16(1):112. PubMed ID: 37990343
[TBL] [Abstract] [Full Text] [Related]
3. Selective hif2a Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel-Lindau-Disease-Associated tumors.
Suárez C; Vieito M; Valdivia A; González M; Carles J
Med Sci (Basel); 2023 Jun; 11(3):. PubMed ID: 37489462
[TBL] [Abstract] [Full Text] [Related]
4. Structural basis for binding of the renal carcinoma target hypoxia-inducible factor 2α to prolyl hydroxylase domain 2.
Figg WD; Fiorini G; Chowdhury R; Nakashima Y; Tumber A; McDonough MA; Schofield CJ
Proteins; 2023 Nov; 91(11):1510-1524. PubMed ID: 37449559
[TBL] [Abstract] [Full Text] [Related]
5. [Precision oncology options in urological cancers].
Franz A; Plage H; Fendler A; Schlomm T; Kornienko K
Urologie; 2023 Jul; 62(7):696-704. PubMed ID: 37294331
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive
Karaghiannis V; Maric D; Garrec C; Maaziz N; Buffet A; Schmitt L; Antunes V; Airaud F; Aral B; Le Roy A; Corbineau S; Mansour-Hendili L; Lesieur V; Rimbert A; Laporte F; Delamare M; Rab M; Bézieau S; Cassinat B; Galacteros F; Gimenez-Roqueplo AP; Burnichon N; Cario H; Van Wijk R; Bento C; Girodon F; Hoogewijs D; Gardie B
Haematologica; 2023 Jun; 108(6):1652-1666. PubMed ID: 36700397
[TBL] [Abstract] [Full Text] [Related]
7. Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia.
Toledo RA; Jimenez C; Armaiz-Pena G; Arenillas C; Capdevila J; Dahia PLM
Endocr Rev; 2023 Mar; 44(2):312-322. PubMed ID: 36301191
[TBL] [Abstract] [Full Text] [Related]
8. Isoform-resolved mRNA profiling of ribosome load defines interplay of HIF and mTOR dysregulation in kidney cancer.
Sugimoto Y; Ratcliffe PJ
Nat Struct Mol Biol; 2022 Sep; 29(9):871-880. PubMed ID: 36097292
[TBL] [Abstract] [Full Text] [Related]
9. Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma.
Tamukong PK; Kuhlmann P; You S; Su S; Wang Y; Yoon S; Gong J; Figlin RA; Janes JL; Freedland SJ; Halabi S; Small EJ; Rini BI; Kim HL
Urol Oncol; 2022 Nov; 40(11):495.e1-495.e10. PubMed ID: 35973929
[TBL] [Abstract] [Full Text] [Related]
10. Organophosphate flame retardant TDCPP: A risk factor for renal cancer?
Zhou X; Zhou X; Yao L; Zhang X; Cong R; Luan J; Zhang T; Song N
Chemosphere; 2022 Oct; 305():135485. PubMed ID: 35764118
[TBL] [Abstract] [Full Text] [Related]
11. Expression and prognostic significance of EPAS-1 in renal clear cell carcinoma.
Chen B; Wang L; Zhao J; Tan C; Zhao P
Ann Ital Chir; 2021; 92():671-675. PubMed ID: 34807005
[TBL] [Abstract] [Full Text] [Related]
12. A drug repositioning success: The repositioned therapeutic applications and mechanisms of action of thalidomide.
Amare GG; Meharie BG; Belayneh YM
J Oncol Pharm Pract; 2021 Apr; 27(3):673-678. PubMed ID: 33249990
[TBL] [Abstract] [Full Text] [Related]
13. Diseases of renal function and bone metabolism after treatment for early onset cancer: A registry-based study.
Liuhto N; Grönroos MH; Malila N; Madanat-Harjuoja L; Matomäki J; Lähteenmäki P
Int J Cancer; 2020 Mar; 146(5):1324-1332. PubMed ID: 31523804
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic significance of VHL, HIF1A, hif2a, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.
Wierzbicki PM; Klacz J; Kotulak-Chrzaszcz A; Wronska A; Stanislawowski M; Rybarczyk A; Ludziejewska A; Kmiec Z; Matuszewski M
Int J Oncol; 2019 Aug; 55(2):371-390. PubMed ID: 31268155
[TBL] [Abstract] [Full Text] [Related]
15. HIF-2alpha: Achilles' heel of pseudohypoxic subtype paraganglioma and other related conditions.
Tella SH; Taïeb D; Pacak K
Eur J Cancer; 2017 Nov; 86():1-4. PubMed ID: 28946040
[TBL] [Abstract] [Full Text] [Related]
16. New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas.
Toledo RA
Endocr Relat Cancer; 2017 Sep; 24(9):C9-C19. PubMed ID: 28667082
[TBL] [Abstract] [Full Text] [Related]
17. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
de Velasco G; Culhane AC; Fay AP; Hakimi AA; Voss MH; Tannir NM; Tamboli P; Appleman LJ; Bellmunt J; Kimryn Rathmell W; Albiges L; Hsieh JJ; Heng DY; Signoretti S; Choueiri TK
Oncologist; 2017 Mar; 22(3):286-292. PubMed ID: 28220024
[TBL] [Abstract] [Full Text] [Related]
18. Loss of vhl in the zebrafish pronephros recapitulates early stages of human clear cell renal cell carcinoma.
Noonan HR; Metelo AM; Kamei CN; Peterson RT; Drummond IA; Iliopoulos O
Dis Model Mech; 2016 Aug; 9(8):873-84. PubMed ID: 27491085
[TBL] [Abstract] [Full Text] [Related]
19. Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.
Garcia-Donas J; Leandro-García LJ; González Del Alba A; Morente M; Alemany I; Esteban E; Arranz JA; Climent MA; Gallardo E; Castellano DE; Bellmunt J; Mellado B; Puente J; Moreno F; Font A; Hernando S; Robledo M; Rodríguez-Antona C
Ann Oncol; 2013 Sep; 24(9):2409-14. PubMed ID: 23788753
[TBL] [Abstract] [Full Text] [Related]
20. Regulation of vascular endothelial growth factor transcription by endothelial PAS domain protein 1 (epas1) and possible involvement of epas1 in the angiogenesis of renal cell carcinoma.
Xia G; Kageyama Y; Hayashi T; Kawakami S; Yoshida M; Kihara K
Cancer; 2001 Apr; 91(8):1429-36. PubMed ID: 11301389
[TBL] [Abstract] [Full Text] [Related]
